XENOVIEW® 3T coil passes Philips compatibility testing
MWN-AI** Summary
Polarean Imaging plc has announced the successful completion of compatibility testing for its FDA-cleared XENOVIEW® 3T Chest Coil with Philips MRI systems, confirming its integration with Philips' advanced 3T MRI platforms, including the MR 7700 and Ingenia Elition X, starting in early 2026. This development builds on previous advancements in Xenon MRI compatibility introduced by Philips in 2022 and significantly enhances access to advanced pulmonary imaging, marking an important milestone in functional lung assessment technology.
The XENOVIEW 3T Chest Coil allows healthcare providers to utilize advanced functional lung ventilation imaging, fostering broader clinical adoption and nudging the company closer to its commercial and clinical goals. With this confirmation, Polarean aims to accelerate market penetration and unlock growth opportunities, enhancing its value proposition in the medical imaging sector.
Christopher von Jako, CEO of Polarean, emphasized that this compatibility expands accessibility to Xenon MRI, assisting more hospitals and imaging facilities in utilizing this innovative technology. Philips' Global MR Clinical Leader, Gwenael Herigault, reiterated that this partnership enhances MRI capabilities, promoting improved diagnostic confidence and patient care through advanced lung imaging tools.
The XENOVIEW coil's compatibility with Philips’ systems signifies a crucial step towards integrating non-invasive and quantitative lung function assessments into routine clinical practice and research. This move is particularly relevant in addressing the needs of over 500 million patients globally suffering from chronic respiratory diseases.
Polarean, founded in 2012 with offices in Durham, NC, and London, UK, is dedicated to enhancing lung health and supporting clinicians in modernizing respiratory imaging through its innovative, non-invasive MRI platform, which relies on hyperpolarized Xenon.
MWN-AI** Analysis
Polarean Imaging plc (AIM: POLX) has made a significant stride in advancing its market position with the announcement that its XENOVIEW® 3T Chest Coil has successfully completed compatibility testing with Philips' latest 3T MRI systems. This milestone, occurring after its FDA clearance, signifies a scaling opportunity for Polarean, particularly as its technology is set to integrate seamlessly into leading imaging platforms beginning in early 2026.
The integration of the XENOVIEW® 3T Chest Coil with leading Philips models such as the MR 7700 and Ingenia Elition X opens up a substantial revenue-generating potential. These advancements position Polarean at the forefront of innovative pulmonary imaging, catering to the pressing demand for accurate assessments of lung function amidst a global landscape of over 500 million patients suffering from chronic respiratory diseases.
Investors should recognize the implications of this compatibility for Polarean's growth trajectory. By simplifying the adoption of advanced imaging technology, healthcare providers will likely be encouraged to prioritize cutting-edge diagnostic tools, leading to an acceleration of market penetration. As operational efficiencies improve and workflow complexities decrease for end-users, Polarean stands to benefit from enhanced clinical adoption rates.
In terms of market valuation, the successful partnership with Philips strengthens Polarean’s credibility and could potentially attract strategic collaborations or partnerships with additional healthcare technology firms looking to innovate within pulmonary imaging.
From a financial standpoint, monitoring Polarean's progress in expanding its customer base and tracking early adoption metrics post-implementation will be critical. Investors should keep an eye on quarterly revenue reports and customer feedback once the technology is live, as these factors will heavily influence the stock’s performance. Overall, Polarean’s growing integration capabilities signify a promising investment opportunity in the medical imaging sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
DURHAM, NC and LONDON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs, announces that its FDA-cleared XENOVIEW® 3T Chest Coil has successfully completed compatibility testing conducted by Philips (Philips Medical Systems Nederland B.V.) and is now confirmed for use with Philips’ latest 3T MRI platforms.
Following extensive validation by Philips, the XENOVIEW® 3T Chest Coil is now confirmed for integration with Philips MRI systems starting in early 2026, including 3.0T platforms such as the MR 7700 and Ingenia Elition X , along with their associated upgrade pathways. Building on Philips’ introduction of Xenon MRI compatibility in 2022 with the MR 7700, the addition of the Polarean XENOVIEW 3T Chest Coil expands access to advanced pulmonary imaging and supports a new era of functional lung assessment. This confirmation, building on the coil’s FDA clearance in 2024, positions the technology for rapid clinical adoption and revenue generation. The XENOVIEW 3T Chest Coil enables healthcare providers to seamlessly adopt advanced functional lung ventilation imaging, supporting broader clinical adoption and advancing the Company’s commitment to innovation in pulmonary imaging.
This milestone marks a major advance in scaling Polarean’s Xenon MRI technology across a major global installed base and enables clinical and research sites using Philips MRI systems to incorporate non-invasive, quantitative assessments of lung function as part of routine care and research. Following this, Polarean is well positioned to accelerate adoption, expand market penetration and enhance significant commercial and clinical value worldwide.
Christopher von Jako, Ph.D., Chief Executive Officer of Polarean commented: “This milestone marks another important advancement in our vision to optimize lung health and prevent avoidable loss by illuminating hidden disease. Compatibility with Philips’ state-of-the-art MRI platforms greatly broadens the accessibility of Xenon MRI and will help more hospitals and imaging centers adopt this powerful technology. Equally significant, our FDA-cleared coil’s seamless integration with Philips systems positions us to drive adoption by reducing workflow complexity for clinicians, accelerating market penetration and unlocking growth opportunities.”
Gwenael Herigault, Global MR Clinical Leader at Philips commented: “ The compatibility of Polarean’s FDA-cleared XENOVIEW® 3T Chest Coil with Philips’ 3T MRI systems reinforces our shared goal of expanding the capabilities of MRI to deliver deeper clinical insights. Together, we’re enabling clinicians to access advanced lung imaging tools that help improve diagnostic confidence and patient care.”
The compatibility statement confirms that the FDA-cleared XENOVIEW 3T Chest Coil can be used with Philips MR 7700, Ingenia Elition X, and compatible software upgrade configurations from 2026 onwards. This development significantly expands the potential reach of Polarean’s technology and supports its goal of making functional lung MRI more widely available to clinicians and patients worldwide.
About Polarean
Polarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercializing innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com .
XENOVIEW IMPORTANT SAFETY INFORMATION
Indication
XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.
Limitations of Use
XENOVIEW has not been evaluated for use with lung perfusion imaging.
CONTRAINDICATIONS
None.
Warnings and Precautions
Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.
Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.
Adverse Reactions
Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration.
Please see full prescribing information at www.xenoview.net .
Contact Information:
Polarean:
Chuck Osborne
Chief Financial Officer
+1 (919) 206-7900, ext. 117
[email protected]
Polarean Investors:
Anna Dunphy / Phillip Marriage
+44 (0)20 7933 8780
[email protected]
Polarean Media Contact:
Alexis Opp
+1 (919) 206-7900, ext. 145
[email protected]
General inquiries: [email protected]
Follow Polarean on LinkedIn here
Attachment
Polarean:Chuck OsborneChief Financial Officer+1 (919) 206-7900, ext. [email protected] Investors:Anna Dunphy / Phillip Marriage+44 (0)20 7933 [email protected] Media Contact:Alexis Opp+1 (919) 206-7900, ext. [email protected] inquiries: [email protected]
FAQ**
How does Polarean Imaging PLC PLLWF's FDA-cleared XENOVIEW® 3T Chest Coil enhance the capabilities of Philips MRI systems in Durham, NC, compared to traditional lung imaging techniques?
What are the potential impacts of the successful compatibility testing on the market adoption of Polarean Imaging PLC PLLWF's XENOVIEW technology across clinical sites in London by 2026?
In what ways does the collaboration between Polarean Imaging PLC PLLWF and Philips facilitate advancements in pulmonary imaging standards in healthcare facilities located in Durham, NC, and London?
How will the integration of the XENOVIEW® 3T Chest Coil with Philips MRI platforms influence investor confidence in Polarean Imaging PLC PLLWF's long-term growth strategy?
**MWN-AI FAQ is based on asking OpenAI questions about Polarean Imaging PLC (OTC: PLLWF).
NASDAQ: PLLWF
PLLWF Trading
6500.0% G/L:
$0.0066 Last:
5,000 Volume:
$0.0066 Open:
